BE analysis – sensitivity analysis [Regulatives / Guidelines]

posted by manu126 – 2012-09-14 10:23 (5037 d 11:14 ago) – Posting: # 9212
Views: 2,510

Hi,
As per EMA guidance document for a 2x2 Cross-over design, BE analysis should be performed on complete cases (and thus using seq, period, trt, and subject within seq as fixed effects).
Since other H-A guidelines don't clearly specify the same, would it be recommanded to have a sensitivity analysis based on all data (complete and incomplete cases) with a random effect model?
The concern might be if your initial analysis shows BE but not the sensitivity analysis....

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
395 visitors (0 registered, 395 guests [including 87 identified bots]).
Forum time: 21:37 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5